Short-chain fatty acids (SCFAs) are produced by the fermentation of dietary fiber by the gut microbiota and arebeneficial to the health of the body. Insufficient SCFAs productions are associated with type 2 diabetes (T2D).We used a long-term high-fat diet to simulate the pathogenesis of T2D and studied the effects of baicalin on gutmicrobiota and metabolites in mice as well as its mechanism, providing a theoretical basis for the treatment ofT2D. Baicalin groups were given 200 mg/kg/day, and control groups were given an equal volume of 0.5%sodium carboxymethyl cellulose solution for 15 weeks. 16S rRNA amplicon pyrosequences was performed toevaluate the gut microbiota composition, and gas chromatography was used to detect SCFAs in stool samples inthe different experimental groups. The abundance of gut microbiota in the high-fat model group was altered, andwas associated with a decreased production of SCFAs. The microbiota abundance of the baicalin group wascloser to that of the control group, increasing the population of SCFA-producing bacteria spp and improvingmetabolic syndrome, including abnormal glucose and lipid metabolism caused by a high-fat diet. Baicalin mayimprove abnormalities in glycolipid metabolism by affecting the production of SCFAs